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CYP2C19 is a drug-metabolising enzyme involved in the metabolism of a number of chemotherapeutic agents including
cyclophosphamide. Variants of the CYP2C19 gene result in a loss of function polymorphism, which affects approximately 3% of the
Caucasian population. These individuals are poor metabolisers (PM) of a wide range of medications including omeprazole (OMP). In
healthy subjects PM can be identified through homozygous variant genotype. However, a discordance between CYP2C19 genotype
and phenotype has been reported previously in a small study of cancer patients. To investigate whether CYP2C19 activity was
decreased in patients with advanced cancer, CYP2C19 genotype was determined in 33 advanced cancer patients using PCR-RFLP
analysis for the two important allelic variants (*2,681G4A and *3,636G4A) and the activity of the enzyme was evaluated using the
CYP2C19 probe drug OMP. The activity of the drug-metabolising enzyme CYP2C19 was severely compromised in advanced cancer
patients, resulting in a PM status in 37% of the patients who had normal genotype. This is significantly (Po0.0005) higher than that
would be predicted from the genotypic status of these patients. There was no evidence of a correlation between compromised
CYP2C19 activity and any of the proinflammatory cytokines or acute phase response proteins studied. However, there was
preliminary evidence of an association between PM status and low body mass (P¼0.03). There is increasing interest in using
pharmacogenetics to ‘individualise medicine’, however, the results of this study indicate that in a cancer population genotyping for
CYP2C19 would significantly underestimate the number of phenotypic PM of drugs, such as cyclophosphamide, which may be
metabolised by this enzyme.
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Variation in drug disposition and response is associated with
many anticancer agents, in part due to large inter-patient
differences in pharmacokinetics (Petros and Evans, 2004). This
may be the result of variable expression of hepatic cytochrome
P450 (CYP), enzymes which play an important role in the
metabolism and elimination of many chemotherapeutic drugs.
CYP2C19 is an important member of the CYP family of enzymes
and is involved in the metabolism of a diverse range of drug
substrates such as the antiulcer agent omeprazole (OMP) (Desta
et al, 2002) and the antimalarial drug proguanil (Ward et al, 1991).
Recently, it has become apparent that CYP2C19 is also important
in the disposition of a number of chemotherapeutic agents,
including cyclophosphamide (Takada et al, 2004; Timm et al,
2005), thalidomide (Ando et al, 2002; Li et al, 2007) and
bortezomib (Uttamsingh et al, 2005).
There is a loss of function genetic polymorphism associated with
the CYP2C19 enzyme, with the result that individuals who are
homozygous variant (var/var) are ‘poor metabolisers’ (PM) of
drugs that are substrates for CYP2C19 (Desta et al, 2002).
Approximately 3% of Caucasians and up to 30% of Asians are
CYP2C19 PM (Xie et al, 1999). Numerous studies have shown a
correlation between variant genotype and PM phenotype in
healthy populations (Xie et al, 1999; Desta et al, 2002). Hence,
the use of a genotyping test for CYP2C19 metaboliser status is
often advocated as a substitute for direct phenotyping with
validated probe drugs such as OMP.
However, genetic variability is not the only factor that can affect
functional activity of drug-metabolising enzymes; gender, age and
co-medications can all play a role in variable CYP expression. In
particular, co-medications can mimic the genetic variability
observed for CYP2C19 with the result that a patient can become
a PM ‘phenocopy’ due to inhibition (competition) of drug
metabolism. However, the importance of chronic disease as a
contributor to variable drug disposition is often overlooked.
There is increasing evidence that the activity of CYP is decreased
in cancer. In a small study of patients (n¼16) with advanced
cancer (Williams et al, 2000), all individuals had normal CYP2C19
genotype but 25% of these patients were CYP2C19 PM
phenocopies. However, the mechanism behind this genotype–
phenotype discordance was not investigated. Previous studies have Revised 2 September 2008; accepted 8 September 2008
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sdemonstrated that the activity of a different enzyme, CYP3A4, is
also decreased in advanced cancer patients and that the decreased
activity correlates with inflammatory response (Rivory et al, 2002).
An inverse relationship between plasma cytokine (TNF-a and
IL-6) concentrations and CYP2C19 activity has been demonstrated
in patients with congestive heart failure (Frye et al, 2002).
Moreover, CYP2C19 mRNA expression is reported to be down-
regulated by cytokines in human hepatocyte in vitro cultures
(Aitken and Morgan, 2007). Hence, limited evidence indicates
that advanced cancer patients may have decreased capacity to
metabolise certain chemotherapeutic agents due to decreased
CYP activity.
The aim of this study was to confirm whether or not CYP2C19
activity is decreased in patients with advanced cancer and to
determine whether a relationship exists between CYP2C19
metaboliser status and inflammatory markers such as cytokines
and acute phase response proteins.
MATERIALS AND METHODS
This study (NTX/05/07/083) was approved by the New Zealand
Health and Disability Multi-Regional Ethics Committee. Following
full informed written consent, 33 patients (18 male, 15 female) with
advanced cancer were recruited into the study. All patients were
self-reported as Caucasian with the exception of one patient
who was Asian. Patients had not received any chemotherapy for at
least 4 weeks before the study and were not on any medications
that are known inducers or inhibitors of CYP2C19. All patients
had adequate hepatic and renal function (creatinine levels
o0.12mmoll
 1, AST/ALT o90Ul
 1, ALP o300Ul
 1, bilirubin
o20mmoll
 1).
Blood (8.5ml) was collected in PAXgene blood tubes and DNA
was extracted using the PAXgenet blood DNA kit (Qiagen, Hilden,
Germany). The CYP2C19 genotype was determined by PCR-RFLP
analysis of the two important allelic variants (CYP2C19*2 and
CYP2C19*3) using previously published methods (Goldstein and
Blaisdell, 1996).
The activity of CYP2C19 (phenotype) was determined using
OMP as the probe substrate (Balian et al, 1995). The plasma
concentration of OMP and the 50-hydroxy metabolite (50-OH) were
measured in the patient’s plasma 2h after oral administration of
OMP (20mg) using previously published methods (Woolf and
Matuszewski, 1998; Motevalian et al, 1999; Orlando and Bonato,
2003) with slight alterations. The log OMP hydroxylation index
(log10 [OMP/50OH]) was used to describe the CYP2C19 metabolic
status of the patients. An index of o1 has been previously shown
to correspond to an extensive metaboliser (EM) phenotype and an
index 41 is a phenotypic PM (Balian et al, 1995; Kortunay et al,
1997).
Serum cytokine levels (IL-1a, IL-1b, IL-6, TNF-a, TGF-b)
were measured by Lincoplex
s multiplex immunoassay (LINCO
Research, St Charles, MO, USA). The levels of hsCRP were
determined by the local medical laboratory testing service using
the standard nephelometry assay. The levels of growth hormone
and albumin were determined using the commercially available
ELISA kits (Growth hormone: R&D Systems, Minneapolis, MN,
USA; Albumin: BioAssay Systems, Hayward, CA, USA).
Statistical analyses were determined using Stata Statistical
Software (Release 9, StataCorp LP) and R (R Development Core
Team, 2007). Continuous data are reported as median and
interquartile range (IQR). Associations between continuous
variables were assessed using Spearman’s rank correlation, and
Mann–Whitney rank-sum tests were used to compare continuous
variables across two groups. The discordance between CYP2C19
genotype vs phenotype was assessed using McNemar’s test and
proportions were compared using Fisher’s exact test. Two-sided
P-values o0.05 were considered statistically significant.
RESULTS
All patients in the study had advanced incurable cancer and a
range of primary tumours including breast, lung, gastrointestinal
tract, kidney, ovarian and melanoma. Patients were aged between
33 and 79 years, with a mean age of 61.5 years and there were 18
male and 15 female patients in the study.
The CYP2C19 genotype of the patients was determined following
PCR-RFLP analysis of the allelic variants (CYP2C19*2 and
CYP2C19*3). Previous studies have shown that individuals who
are homozygous variant (var/var) for the CYP2C19 gene have null
CYP2C19 activity and are PM. In contrast, individuals with at least
one wild-type allele at these loci are classed as EM, that is, wt/wt
and wt/var. One patient was homozygous variant (var/var) for the
CYP2C19*3 allele; hence, they are a genotypic PM (gPM) and
would be predicted to have null CYP2C19 activity. Genetic PM are
more common in Asian populations, and this was the one Asian
patient in the study. The CYP2C19*3 allele was not observed in any
other patient; however, this variant is uncommon in Caucasian
populations. The remaining patients were wt/wt (n¼20) or wt/var
(n¼12) for the CYP2C19*2 allele and hence are all classed as
genotypic EMs.
The activity of the CYP2C19 enzyme in the patients was then
determined directly using OMP as a probe drug. Two patients had
no detectable drug or metabolite in the plasma and were excluded
from any further analysis. The medians of the log OMP
hydroxylation index were 0.86 and 0.47 for the wt/var and wt/wt
genotypes, respectively (data shown in Figure 1). The one
genotypic PM (var/var) in this study had a log OMP hydroxylation
index of 2. This is consistent with the predicted null CYP2C19
activity in this patient. Comparison of the genotype predicted and
the measured metabolic status (Table 1) found a statistically
significant discordance (Po0.0005). Of the 30 cancer patients with
genotypic EM status 11 (37%) were CYP2C19 PM ‘phenocopies’;
there was no statistically significant difference between the
proportions who were phenotypic PM in the two genotypic EM
groups (6 out of 18 for wt/wt and 5 out of 12 for wt/var, P¼0.6).
Five patients with wt alleles had liver metastases and the
hydroxylation index in these patients were 0.11, 0.59, 1.22, 1.32
wt/wt wt/var var/var
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Figure 1 Distribution of CYP2C19 activity in patients with advanced
cancer. Omeprazole (OMP) was used as a probe substrate for the
CYP2C19 enzyme and activity was determined using the log OMP
hydroxylation index (log OMP HI) at 2h post-dose. Individuals with a log
OMP HI 41 are classed as phenotypic poor metabolisers of this drug.
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sand 1.48, that is, two patients were phenotypic EM and three were
phenotypic PM.
A number of studies have demonstrated that acute inflammation
can downregulate P450 enzyme expression, (reviewed by Morgan
et al, 2008). To determine whether the decreased CYP2C19 activity
observed in the cancer patients was related to the inflammatory
response, the serum levels of a number of proinflammatory
cytokines and the acute phase response protein, CRP were
measured. There was considerable variability in the levels of
IL-1a, IL-1b, IL-6, TNF-a and TGF-b and these were clearly
elevated in some patients, with a median (IQR) for IL-1a of 107.2
(19.8–408.2); IL-1b, 1.1 (0–2.7); IL-6, 40.0 (13.3–89.1); TNF-a, 6.5
(4.0–10.8) and TGF-b, 495.0 (427.5–627.5) pgml
 1. The acute
phase protein, hs-CRP, was above the upper limit of normal
(10mgl
 1) in 15 patients; however, only five individuals had levels
440mgl
 1. There was no statistically significant correlation
between the levels of any individual cytokine and CYP2C19
metabolic activity (log OMP hydroxylation index) (Figure 2,
Table 2). Multiple regression analysis also did not reveal any
evidence of correlation between inflammatory markers and
CYP2C19 activity in the patients. The acute phase inflammatory
response also results in hypoalbuminaemia and this has been
associated with decreased activity of other CYP enzymes in cancer
patients (Rivory et al, 2002). The median albumin concentration in
this study was 45.4gl
 1 (IQR 43.7–48.8) and only one patient was
hypoalbuminaemic (below 35gl
 1). However, there was no
evidence of association between albumin concentrations and log
OMP hydroxylation index in the patients (Table 2).
Owing to the lack of association between proinflammatory
cytokines and CYP2C19 activity in the advanced cancer patients,
the samples were also analysed for the levels of growth hormone.
Administration of growth hormone has been associated with a
decrease in OMP hydroxylation index in healthy volunteers
(Ju ¨rgens et al, 2002). In addition, growth hormone has been
reported to be elevated in cancer patients (Du ¨lger et al, 2004).
There was considerable variability in the levels of growth hormone
in the cancer patients (median¼0.9, IQR¼0.3–3.0mgl
 1); how-
ever, all values were within expected daily variation of this
hormone and no patients had levels elevated above normal values
(424mgl
 1). Moreover, there was no evidence of association
Table 1 The predicted CYP2C19 metabolic status (genotype) vs actual CYP2C19 activity (phenotype) in cancer patients
Genotype Phenotype
Alleles Predicted metaboliser status Extensive metaboliser (log OMP HIo1) Poor metaboliser (log OMP HI41)
wt/wt or wt/var Extensive metaboliser 19 11
var/var Poor metaboliser 0 1
There was a significant discordance between CYP2C19 genotype and phenotype (McNemar’s test Po0.0005). Two patients with wt/wt genotype had no detectable drug or
metabolite in plasma and hence could not be phenotyped and were not included in this comparison.
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Figure 2 Relationship between CYP2C19 activity and the levels of inflammatory cytokines and CRP. The P-values from Spearman’s rank correlation test
are shown on the graphs.
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sbetween the levels of growth hormone and CYP2C19 activity (log
OMP hydroxylation index) in the cancer patients (Table 2).
Another indicator of disease progression in cancer is cachexia,
particularly skeletal muscle loss. Although this study did not
directly assess the patients’ cachexic status, body mass index
(BMI) was determined in these patients at the time of recruitment.
There was preliminary evidence of an association between BMI
and CYP2C19 activity in the advanced cancer patients; according
to the standard cutoff for BMI, among those with low BMI (o25)
62% (8 of 13) were PM compared with 22% (4 of 18) in patients
with a high BMI (425) (P¼0.03).
DISCUSSION
The results of this study indicate that the activity of the drug-
metabolising enzyme CYP2C19 was compromised in advanced
cancer patients. Of the advanced cancer patients studied who had
genotypic EM status, 37% were PM phenocopies. In healthy
subjects, only 3% of Caucasian subjects are CYP2C19 PM and this
is due to the presence of the CYP2C19 loss of function genotype
(homozygous variant) in these individuals (Xie et al, 1999).
In a healthy population, the activity of CYP2C19 is bimodally
distributed and the antimode of the population (log OMP
hydroxylation index¼1.0) can delineate between CYP2C19
genotypic EM (wt/wt and wt/var) and genotypic PM (var/var)
genotypes. The log OMP hydroxylation index in genotypic EM
is reported to be between  0.55 and 0.40 (Balian et al, 1995).
In contrast, the activity of the enzyme in the advanced cancer
population was not bimodally distributed and the activity of the
enzyme was low (log OMP hydroxylation index range  0.10 to 2.0)
indicating that the overall activity of this enzyme was compro-
mised in this cancer population.
This is not the first study to demonstrate the effect of advanced
cancer on drug-metabolising enzymes in advanced cancer. A
discordance between CYP2C19 genotype and phenotype has been
reported previously in a small study (n¼16) of advanced cancer
patients (Williams et al, 2000). The higher incidence of phenotypic
PM in this study (37%) compared with an incidence of 25%
(Williams et al, 2000) may reflect small sample variation. However,
the high incidence of PM in both studies indicates that decreased
CYP2C19 activity in cancer patients is a noteworthy effect that
could have clinical significance for chemotherapeutics, such as
cyclophosphamide, which may be substrates for CYP2C19.
A number of clinical factors may influence the activity of hepatic
enzymes, including co-medications and liver disease. However, no
patients in this study had taken any medications that could induce
or inhibit CYP2C19 and patients had not received any cancer
chemotherapy for at least 4 weeks before the study. Inclusion
criteria for the study also required patients to have good hepatic
and renal function, in contrast to the previous small study
(Williams et al, 2000) in which a number of patients had elevated
ALP enzyme and two patients had hepatitis. Although five patients
in this study had liver metastases, this did not appear to correlate
with compromised CYP2C19 metaboliser status and there was also
no relationship with the location of the primary cancer and
metaboliser status.
An additional factor hypothesised to affect the activity of hepatic
CYP enzymes is inflammation. The activity of another hepatic
drug-metabolising enzyme CYP3A is decreased in cancer patients
(Rivory et al, 2002) and this decreased activity correlates with the
acute phase response status of the patients. In addition, an inverse
relationship between CYP2C19 activity and plasma TNF-a or IL-6
concentrations has been reported in patients with congestive heart
failure (Frye et al, 2002). A more recent study (Aitken and Morgan,
2007) using cultured human hepatocytes has reported that a
number of cytokines can downregulate CYP2C19 mRNA expres-
sion in vitro. However, in this study in advanced cancer patients,
we could not find evidence of a relationship between CYP2C19
activity and serum levels of cytokines or the acute phase response
protein CRP. Nevertheless, alternate cytokines or other inflamma-
tory mediators may be involved in the observed decreased
CYP2C19 function in advanced cancer.
The levels of cytokines observed in our study were in the
same range as the data reported previously in cancer patients
(Rivory et al, 2002) and in patients with congestive heart failure
(Frye et al, 2002). But, it should be noted that the levels (pgml
 1)
of the cytokines observed in cancer patients in this study is
approximately 100-fold lower than the 10ngml
 1 concentrations
of IL-6 and TGF-b required to significantly downregulate
CYP2C19 mRNA in vitro (Aitken and Morgan, 2007). However,
the circulating half-life of cytokines is relatively short and the
levels may also be underestimated due to the presence of soluble
receptors for these inflammatory mediators. Moreover, little is
known about the temporal relationship between circulating
cytokine levels and downregulation of CYP in vivo.
Further studies in larger cohorts of patients are required to
explore these hypotheses more fully.
We also did not observe a relationship between decreased
CYP2C19 activity and the acute phase response protein CRP. This
may again be due to the relatively low levels of this inflammatory
marker observed in the patients. The relationship between
CRP levels and decreased CYP3A activity demonstrated previously
(Rivory et al, 2002), occurred at relatively high concentrations
of CRP, in contrast only five patients in this study had CRP
levels 440mgl
 1. The levels 440mgml
 1 are considered to be
indicative of acute inflammation (Gill, 2000). Hence, the inflam-
matory mediators in this population of advanced cancer patients
Table 2 Comparison of the phenotypic poor metabolisers and extensive metabolisers
Phenotype
Poor metabolisers (log OMP HI 41) Extensive metabolisers (log OMP HI o1)
median (IQ range) n¼12 median (IQ range) n¼19 P-value
a
IL-1a 111.2 (17.7, 287.3) 107.2 (20.8, 794.5) 0.61
IL-1b 1.4 (0, 39.2) 1.1 (0, 2.3) 0.35
IL-6 65.9 (12.0, 82.7) 38.0 (13.4, 134.9) 0.97
TNF 7.4 (3.8, 12.5) 6.5 (4, 9.3) 0.57
TGF 497.5 (338.8, 641.3) 490 (440, 553) 0.63
CRP 9.1 (2.3, 39.3) 8.7 (2.0, 24.0) 0.76
Albumin 46.9 (43.4, 50.2) 44.8 (43.0, 48.9) 0.41
Growth hormone 988.8 (222.5, 3075) 955.7 (496.3, 4117.2) 0.44
BMI 27.7 (21.7, 30.0) 23.7 (22.0, 27.6) 0.09
Median and interquartile (IQ) ranges are shown for levels of inflammatory cytokines, albumin concentration, growth hormone concentration and body mass index (BMI).
aMann–Whitney rank-sum test.
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smay not have achieved levels high enough to have an effect on
CYP2C19 activity.
Administration of growth hormone can decrease CYP2C19
activity in man (Ju ¨rgens et al, 2002). In addition, growth hormone
has been reported to be elevated in cancer patients (Du ¨lger et al,
2004). However, there also did not appear to be a relationship
between growth hormone levels and decreased CYP2C19 activity
in these patients.
Thus currently, the mediators of the decreased activity of
CYP2C19 in advanced cancer are not apparent. However, there
was a significant relationship between body mass and CYP2C19
PM status. Although BMI is not a good indicator of cachexia
particularly in the late stage disease, as weight loss due to increased
muscle and fat catabolism, may be obscured by weight gain due
to ascites. Nonetheless, the relationship between low BMI and
poor metabolic status is intriguing. Cachexia is associated with
increased proinflammatory cytokines particularly IL-6 and TNF-a,
increased CRP, decreased albumin production and also decreased
GH levels (Du ¨lger et al, 2004) and hence may be a more general
biomarker of the inflammatory status in these patients. Alter-
natively, the overall increased protein catabolism in cachexia may
play a more direct role in the compromised CYP2C19 activity. The
preliminary finding of a possible association between compro-
mised CYP2C19 activity and low BMI requires further study in a
larger cohort of patients.
The implications of compromised CYP2C19 activity are of
direct relevance to cancer chemotherapy. The decrease in enzyme
activity may significantly impact on the efficacy and toxicity
of chemotherapeutic agents that are substrates for this enzyme.
Moreover, a pharmacogenomic approach is often advocated to
‘personalise’ medicine to reduce the incidence of under- and over-
dosing of patients. However, it is apparent that in cancer patients
this approach would considerably underestimate the number of
PM of drugs that are substrates for this enzyme.
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